Genmab — August 2019
-
Fordi jeg er SÅ klar til at raketten letter..
-
New trial - Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease (DARZAD) - https://clinicaltrials.gov/ct2/show/NCT04070378
-
another new trial - S1803, Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC) - https://www.clinicaltrials.gov/ct2/show/NCT04071457?term=daratumumab+OR+ofatumumab+OR+arzerra+OR+darzalex+OR+tisotumab+OR+Genmab&lupd_s=08%2F28%2F2019&rank=1
-
The Auriga study will finish a little sooner https://www.clinicaltrials.gov/ct2/show/NCT03901963?term=mmy3021&rank=1
-
God morgen

-
God morgen.

-
-
@E L Does the link translate into that Bemcentinib + Keytruda is better than Enapotamab vedotin.
-
-
Ok. Thank you.
-
BerginBio is second line. EnaV is 4th plus lines. Therefore the EnaV patients are much more sick.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind